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Abstract 
Metastasizing tumour cells must transmigrate the dense extra-cellular matrix that 
surrounds most organs. The use of 3-dimensional (3D) collagen gels has revealed that 
many cancer cells can switch between different modes of invasion that are 
characterized by distinctive morphologies (rounded versus elongated). The adhesion 
protein NEDD9 can regulate the switch between elongated and rounded invasion in 
melanoma cells and thus we questioned the role of NEDD9 in the invasion switch of 
glioblastoma and neuroblastoma tumours that similarly derive from populations of 
neural crest cells. siRNA mediated depletion of NEDD9 failed to induce cell rounding 
in the glioma or neuroblastoma cells, contrasting the effects that have been described 
in melanoma and fibroblasts. Given that Rac GTPase has been described to mediate 
the switch between elongated and rounded invasion we tested whether the Rac 
morphology switch is functional in the glioma and neuroblastoma cells under 
investigation. Using both dominant negative Rac and Rac1-specific siRNA we 
confirm the presence of this morphological switch in the neuroblastoma, but not the 
glioma cells. In the absence of a morphological change following NEDD9 depletion 
we instead quantified cell migration speed and demonstrated a significant decrease in 
migration rate. Our data therefore reveal that NEDD9 can regulate 3D migration 
speed independently of the Rac1 morphology switch.  
IMPLICATIONS: Our data suggests that targeting NEDD9 does not stimulate 
adaptive changes in glioma and neuroblastoma invasion and thus may be 
therapeutically useful for these tumours. 
 
  
3 
 
Introduction 
The adhesion docking protein NEDD9/HEF1/Cas-L is a member of the Cas family of 
proteins that includes p130Cas/Bcar1, Efs/Sin and HEPL/CASS4.1 Increasing studies 
point to a critical role for NEDD9 as a regulator of migration and invasion in diverse 
cancer types.2  In addition to this pathological role, NEDD9 was first identified in a 
screen for neural precursor cell and developmentally down-regulated genes3 and was 
subsequently shown to regulate migration in neural pre-cursor/neural crest cells.4 The 
neural crest cells are a highly migratory cell type that give rise to a variety of cell 
lineages that includes peripheral neurons, glia and melanocytes.5 In turn, 
transformation of neural crest cell populations is thought to give rise to 
neuroblastoma, glioma brain tumours and melanoma. Progression to invasive disease 
remains a significant impediment to successful treatment for each of these tumour 
types. The neuroblastomas are the most common extra-cranial tumour of childhood 
and the majority of patients present with metastatic disease. In contrast to other 
tumour types, gliomas rarely metastasize to secondary sites but instead the high grade 
gliomas (grade III and IV) extensively infiltrate the surrounding health brain tissue. 
Based on recent insights into the role of NEDD9 in the invasive behaviour of 
melanoma6, 7 we have investigated the role of NEDD9 in glioma and neuroblastoma 
invasion that exhibits the features of invading neural crest cells. 
 
NEDD9 is expressed during embryonic brain development but is down-regulated in 
the normal adult brain3 upon lineage commitment of progenitor cells.8 NEDD9 is 
specifically expressed in nestin-positive neural crest cells that emigrate from the 
dorsal tube.4  The characteristic invasive morphology of the neural crest cells is 
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suggested to closely resemble that of invasive glioma cells. 9, 10 Uniquely among the 
Cas family proteins, NEDD9 was required for the invasion of U87MG glioblastoma 
cells through brain homogenates.11 NEDD9 is elevated in high grade glioma cells and 
high level expression in low grade glioma correlated with significantly poorer 
prognosis and increased invasion.12 In contrast, the morphological regulation of 
invasive neuroblastoma is comparatively less well defined. Notably, NEDD9 was 
defined as an all trans-retinoic acid responsive gene upregulated in response to 
retinoic acid induced neuritogenesis in neuroblastoma cells.13 
 
3D collagen gels that mimic the in vivo interstitial environment have been key in 
demonstrating the plasticity of cancer cell invasion mechanisms.7, 14, 15 It has emerged 
that cancer cells may employ differential modes of invasion characterised by distinct 
cellular morphologies. In particular NEDD9 promotes elongated/mesenchymal 
invasion in melanoma cells.7 Elongated invasion is regulated by Rac GTPase activity 
and Rac GTPase inhibition stimulates the switch to a rounded/amoeboid, Rho kinase-
dependent mode of invasion. NEDD9 stimulates Rac GTPase activity via the 
recruitment of the Rac GTP exchange factor DOCK3.7 Depletion of NEDD9 from 
melanoma cells7 and mouse embryo fibroblasts16 leads to a switch from an elongated 
phenotype to a rounded cell phenotype in 3D collagen cultures.  
 
A number of studies have identified a key role for Rac activity in regulating high 
grade glioma invasion. While Rac1 depletion reduced glioma cell line invasion17, this 
treatment alone was insufficient to induce a switch to a rounded invasion mode.15 It 
was only following inhibition of all Rac activity via knock-down of both Rac1 and 
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Rac3 isoforms or expression of dominant negative Rac that U87MG cells adopted the 
classic rounded invasion mode.15 Similarly, simultaneous Rac1 and Rac3 depletion, 
together with Rho kinase inhibition, was required in order to comprehensively arrest 
3D collagen invasion by highly invasive cells isolated from the peri-tumoral region of 
a high grade glioma.18 While there appears to be no reports to date having examined 
whether neuroblastoma cells undergo morphological transition in 3D collagen culture 
following Rac inhibition, in 2D conditions Rac1 and Rac3 isoforms have apparently 
opposite effects on cellular morphologies.19 These studies therefore suggest that Rac 
GTPase may be a critical determinant of high grade glioma and neuroblastoma 3D 
morphologies.  
 
In the present study we have investigated the role of NEDD9 in regulating 3D 
invasive morphologies of high grade glioma and neuroblastoma cells. Using publicly 
available expression data we show a significant association between NEDD9 
expression and poor survival rates for both tumour types. Importantly, in contrast to 
effects seen in melanoma, NEDD9 depletion fails to induce a morphological switch in 
either high grade glioma or neuroblastoma cells. Notably, while the neuroblastoma 
cells exhibit a robust morphological switch in response to Rac inhibition, this affect is 
much reduced in the high grade glioma cells. Instead, we find that NEDD9 depletion 
significantly reduces migration speed of cells as they negotiate the 3D collagen 
environment. Collectively, our data reveal that NEDD9 plays a significant role in 
regulating cell speed in 3D environments, independently of the Rac-mediated 
morphological switch. 
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Materials and Methods 
Cell culture and antibodies. Cultured glioblastoma (A172, CCF-STTG1, DBTRG, 
MO59J, MO59K and T98G) cell lines were kindly provided by Dr Kerrie McDonald 
(Lowy Cancer Centre, UNSW, Australia). Correct identity of A172 and DBTRG lines 
was independently verified by CellBank Australia (Sydney, Australia).  The 
neuroblastoma cell lines (NB69, SH-EP, SH-SY5Y, SK-N-AS, SK-N-FI and SK-N-
SH) were kindly provide by Dr Loretta Lau (Kids Research Institute, Sydney, 
Australia). Cell lines were maintained in DMEM supplemented with 10% FBS. 
Growth of cells in 3D collagen gels, media for live imaging and invasion assays 
through 3D collagen gels was based on protocols previously reported to identify 
invasion plasticity20 and as we have previously employed 21. The following antibodies 
were used: anti-NEDD9 (ImmuQuest; clone 2G9 and Cell Signaling Technology, 
clone 29G); Anti-pan-Rac (#610650 BD Bioscience), anti-HSP70 and anti-α-tubulin 
(Sigma-Aldrich); HRP-conjugated anti-mouse and anti-rabbit (Amersham and Biorad) 
and anti-rat Alexa-Fluor 647 conjugate (Molecular Probes, Invitrogen).  
 
Protein extraction, siRNA and immunoblotting. Conditions of protein extraction and 
immunoblotting were carried out as previously described.22 Protein concentrations 
were determined using the BCA Protein Assay Kit (Pierce Biotechnology IL, USA) 
and protein concentrations equalized prior to loading on gels. Control siRNA and 
custom-designed NEDD9 siRNAa (targeting the sequence 
CCAGGACAUUCGCAACAAA, as previously described16) and siRNAb 
(GAGACACCAUCUACCAAGUUU, as previously described7) were purchased from 
Dharmacon (Thermo Scientific). 10 nM siRNA was transiently transfected twice at 24 
h intervals, using Lipofectamine2000 (Life Technologies) as per manufacturer’s 
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instructions. Inhibition of Rac GTPase activity was achieved by transfecting cells with 
plasmid vector encoding dominant negative Rac (DNRac) as previously described.23 
Custom designed Rac siRNAs were purchased from Invitrogen comprising sequences 
targeting human Rac1 (5’-GAGGCCUCAAGACAGUGUUUGACGA-3’) and Rac3 
(5’-CCUCCGCGACGACAAGGACACCAUU-3’); control sequences for Rac 
knockdown experiments were Qiagen Allstar Non-targeting Control siRNA (Qiagen). 
Rac siRNAs were used at a final concentration of 100nM when used individually and 
50nM each when used in combination. Successful knock-down was independently 
confirmed for all experiments. 
 
Live cell imaging, migration and rounding analysis. Time-lapse images were 
captured using an ORCA ERG cooled CCD camera (Hamamatsu, SDR Clinical 
Technology NSW, Australia) and Olympus IX81 inverted microscope equipped with 
an environmental chamber heated to 370C. Transmitted light images were captured at 
indicated time intervals. Cells undergoing division or apoptosis were excluded from 
analyses and random migration analyses were performed on sparsely plated cultures. 
Post image capture, nuclear translocation was tracked in time-lapse stacks using 
Metamorph V6.3 software (Molecular Devices). Calculation of Mean Squared 
Displacement (MSD) was performed as previously described.24 We note that only 
elongated cells were tracked in the analysis of 3D migration. Glioblastoma cell 
morphologies in 3D collagen gels were manually scored as either elongated, 
displaying extending protrusions and an elongated cell body, or rounded, with a 
rounded cell body and the absence of protrusions. Cells were counterstained with 
propidium iodide (Sigma-Aldrich) and apoptotic cells excluded from morphological 
analyses. Reduced cell branching exhibited by the SH-EP cells facilitated semi-
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automated analysis of cell shapes. In this case z-stacks of fluorescently-tagged 
phalloidin stained cells were captured using Leica SP5 confocal scanning laser 
microscope (Leica Microsystems, Germany) with 10X air objective. Maximum 
projections of z-stacks were filtered using Metamorph V7.7 software by Fast Fourier 
Transformation followed by low pass basic filter, auto-thresholding for light objects 
and drawing regions around objects. Any joined cells were manually separated and 
cell shape factor (4πA/P2: A = area, P = perimeter) then measured using integrated 
morphology analysis. Data were filtered to exclude anything smaller than 15 pixels in 
area. Cells with shape factor >0.75 were scored as rounded. 
 
Image preparation. Final micrograph images and grey level adjustments were 
prepared in Adobe Photoshop.  
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RESULTS 
NEDD9 expression in glioma and neuroblastoma 
We first examined the relationship between NEDD9 expression and patient survival 
in both glioma and neuroblastoma. This was achieved using publicly available data 
from the REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT) 
homepage (http://rembrandt.nci.nih.gov) and the Oncogenomics website 
(http://home.ccr.cancer.gov/oncology/oncogenomics/) for neuroblastoma. In 
agreement with previously published results12, high level NEDD9 expression was 
significantly associated with poorer survival rates in a cohort of glioma patients 
(Figure 1A). Moreover, comparison of the percentage of low grade gliomas (grade 
II/III) and high grade gliomas (grade IV, glioblastoma) between cases with 
intermediate versus high level NEDD9 expression revealed significantly more high 
grade glioma cases in the high NEDD9 dataset (Figure 1B). Notably, we found a 
significant association between high NEDD9 expression and reduced patient survival 
in the subset of neuroblastomas that lack N-myc amplification (n = 101) (Figure 1C). 
Based on these observations, NEDD9 expression was then profiled in human 
glioblastoma cell lines, and neuroblastoma lines that lack N-myc amplification. The 
highest level of NEDD9 expression (seen as a doublet on western blot25) was detected 
in the A172, DBTRG and MO59J glioblastoma cells and in the SH-EP and SK-N-SH 
neuroblastoma cells (Figure 1D). The SK-N-SH cells are a mixed culture from which 
both the SH-EP and SH-SY-5Y cell lines were derived.26 It is therefore interesting 
that while the SH-EP and SK-N-SH lines are positive for NEDD9 the SH-SY-5Y cells 
exhibit little detectable NEDD9, suggesting that SK-N-SH cells may be a mix of high 
and low NEDD9 expressing cells.  
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NEDD9 depletion does not induce rounding 
It has previously been established that NEDD9 regulates the morphological switch 
from elongated to rounded 3D invasion in melanoma cells.7 Thus we questioned the 
effect of NEDD9 depletion on glioblastoma cell morphology, focusing on the A172 
and DBTRG cells due to their high endogenous levels of NEDD9 expression. Under 
3D culture conditions, ~60% of the A172 cells and ~40% of DBTRG cells have an 
elongated morphology (Figure 2B and 2C). Inspection of cells following NEDD9 
depletion suggested little evidence of a switch to a rounded morphology in either cell 
line, despite robust NEDD9 depletion (Figure 2A and 2B). Rather, quantification 
indicated that NEDD9 depletion caused a small decrease in the percentage of round 
A172 and DBTRG cells (Figure 2C). Thus, NEDD9 depletion does not appear to 
induce rounding in either A172 or DBTRG glioblastoma cells. 
 
We next questioned the effect of NEDD9 depletion on neuroblastoma cell 
morphology, using the SH-EP line that has high endogenous NEDD9 expression 
(Figure 1C). In 3D collagen gels, the SH-EP cells have a mixed morphology with ~ 
50% of cells exhibiting an elongated phenotype (Figure 2D and 2F).  NEDD9 
depletion was achieved using two independent siRNA sequences (siRNAa and 
siRNAb) (Figure 2E). Again, visual inspection of the cultures suggested little effect 
on cell rounding (Figure 2D). Quantification revealed that NEDD9 depletion with 
siRNAa caused a small decrease in the percentage of round cells, while siRNAb 
caused a small increase in cell rounding (Figure 2F). However this only represented a 
change from an average of 53% rounded under control conditions, to 50% and 57%, 
respectively. Thus, in contrast to effects on melanoma cells7 and fibroblasts16 the 
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present data suggest that NEDD9 depletion has a minimal effect on the morphology 
of either glioblastoma or neuroblastoma cells. 
 
Differential response to Rac1 inhibition 
We considered that the lack of effect of NEDD9 depletion on the cell morphologies 
may reflect absence of the morphological switch (elongated/mesenchymal to 
rounded/amoeboid) in these cells. Rac GTPase is a major regulator of the switch 
between elongated and rounded invasion7, 15 and NEDD9 is an upstream regulator of 
this pathway in melanoma cells.7 Thus we tested whether inhibition of Rac GTPase 
activity via the expression of dominant negative Rac (GFP.DNRac) induced 
morphological transition in either the A172 or SH-EP cells. Dominant negative Rac 
resulted in only a modest increase in the numbers of rounded A172 glioblastoma cells 
(Figure 3A). By contrast, approximately 80% of SH-EP cells expressing GFP.DNRac 
exhibited a rounded phenotype (Figure 3A). This is highlighted in 10 random fields of 
view for GFP versus GFP.DNRac transfected SH-EP cells where the GFP-positive 
control cells display a mix of elongated and rounded morphologies, while all visible 
GFP.DNRac-positive cells are rounded (Figure 3B). These data suggest that while the 
Rac-dependent morphology switch is strongly present in the SH-EP cells, loss of Rac 
activity appears to have less effect in the A172 cells. 
 
Previous studies targeting Rac isoforms revealed that switching U87MG glioblastoma 
cells from an elongated to a rounded morphology requires the depletion of both Rac1 
and Rac3 isoforms15. This suggested the possibility that the failure to induce rounding 
in A172 cells following NEDD9 depletion may be due to NEDD9 regulating a 
specific isoform of Rac and that the presence of other Rac isoforms may therefore 
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compensate. Rac 3 is highly expressed in the brain27 and both Rac1 and Rac3 are 
suggested to play a key role in glioblastoma invasion.28 Thus we questioned whether 
A172 rounding may require the inhibition of both Rac1 and Rac3 isoforms. Depletion 
was achieved using siRNA-specific for each Rac isoform as previously described.15 
Due to the absence of commercially-available isoform specific antibodies, 
confirmation of knock-down was determined by comparing the levels of total Rac 
protein (Figure 4A). Notably, only siRNA targeting Rac1, not Rac3, significantly 
decreased levels of total Rac protein (Figure 4B). Since it has previously been 
suggested that Rac3 depletion may lead to a corresponding increase in Rac1 protein15, 
we proceeded with the double knock-down of Rac1 and Rac3 and examined the 
morphology of cells resulting from all three siRNA conditions. This analysis revealed 
that combined depletion of Rac1 and Rac3 had no effect on cellular morphologies in 
3D collagen gels (Figure 4C and 4D). Similarly, individual targeting of the Rac 
isoforms had no effect on A172 morphology. It is interesting that Rac knock-down 
was not able to recapitulate the small increase in rounding that was seen in cells 
expressing dominant negative Rac (Figure 3), despite a significant reduction in total 
Rac protein levels (Figure 4A). Together, these data emphasize that the A172 cells 
have a limited response to the Rac-dependent morphology switch.  
 
Given that the Rac morphology switch appears to be robustly functioning in the SH-
EP cells, we next questioned the isform-specific role of Rac in SH-EP 3D 
morphology. While Rac1 depletion significantly reduced total Rac protein levels, 
Rac3 depletion had no effect (Figure 5A and 5B) either that Rac3 may not be 
expressed in the SH-EP cells, or there is a compensating increase in Rac1 as 
suggested earlier. Critically, Rac1 depletion significantly increased the numbers of 
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rounded SH-EP cells (Figure 5C and D), mimicking the effect of DNRac. In 
summary, these data suggest that the morphological switch in SH-EP cells is Rac1 
dependent. 
 
NEDD9 depletion slows 3D migration. 
Our investigations have revealed distinct differences in the morphological control of 
A172 glioblastoma and SH-EP cells in 3D collagen gels, despite both lines expressing 
high levels of endogenous NEDD9 protein. Moreover, the data suggest that NEDD9 
does not regulate a Rac1-dependent molecular switch in these cell lines. This then 
raises the question of whether NEDD9 plays any role in the 3D migration of these 
cells. To examine this question we measured 3D migration speed by analysis of time-
lapse images of the cells as they migrate through the 3D collagen gels. This revealed 
that the A172 cells move more slowly through the gels following NEDD9 depletion. 
Reduced NEDD9 levels caused a shift in the Mean Squared Displacement (MSD) and 
a significant decrease in average cell speed (Figure 6A and 6B). Similarly, the 
DBTRG cells (that also do not undergo rounding following NEDD9 depletion, as 
demonstrated in Figure 2) slow down following NEDD9 depletion (Figure 6A and 
6B). Finally, we also observed that the SH-EP cells slow down in response to 
treatment with either siRNAa or siRNAb targeting NEDD9. When tracking the SH-
EP cells following NEDD9-depletion there appeared to be two populations of cells. 
One fast moving group appeared to be relatively unaffected by NEDD9 depletion. 
However, the slower moving group was more affected. Comparison of the frequency 
distrition of speeds between the different conditions revealed that the greatest changes 
occurred at speeds ≤ 0.4 μm/min (Figure 6C). Accordingly, the average speed was 
significantly lower in the <0.4 μm/min populations treated with either NEDD9-
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targeting siRNA (Figure 6D). Notably, following NEDD9 knock-down the cells 
continued to display rounded cell bodies with a leading membrane protrusion, with 
occasional pausing as the cells retracted the protrusion and adopted a rounded shape, 
but had slower progress through the gel (Figure 6E). Together these data reveal that 
NEDD9 depletion reduces 3D migration speed, without stimulating transition to 
rounded invasion.  
 
Discussion 
Based on insights from developmental biology, in the present study we have 
investigated the role for NEDD9 in the migration of tumours that derive from neural 
crest cell populations. We employed 3D collagen gel models to investigate invasion 
plasticity in response to altered NEDD9 expression.7, 20 Importantly, while we show 
cell-type differences in regard to invasion plasticity control by Rac GTPase activity, 
the cell lines investigated in the present study are united by their lack of 
morphological switch following NEDD9 depletion. Thus our data suggest that 
NEDD9 may not universally regulate the transition between morphologically distinct 
invasion phenotypes. Instead, we find that NEDD9 is an important determinant of the 
speed with which cells negotiate the 3D extracellular environment. 
 
Prior to initiating investigations of NEDD9 and migration in glioma and 
neuroblastoma cell lines, we first determined whether there is any clinical association 
between NEDD9 and survival in these tumour types. Related to this, a recent study 
showed that higher level NEDD9 in lower grade glioma tumours is associated with 
reduced progression free survival.12 In agreement with this, analysis of 
REMBRANDT data presented here demonstrated an association between NEDD9 
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expression and survival when all glioma tumours were grouped together. When 
NEDD9 levels were examined specifically in the high grade gliomas (III and IV) 
there was no significant association between expression and survival (data not 
shown). Importantly, recent advances in tumour profiling have revealed that high 
grade gliomas can be further stratified into risk groups based on gene expression 
profiles. For example, one such classification scheme defines cells as pro-neural, 
proliferative and mesenchymal, with corresponding increase in aggressiveness.29 
Potentially, NEDD9 expression may prove to be more prominent in one of these sub-
classes, particularly given recent reports suggesting a correlation between NEDD9 
and nestin expression in glioma.12 We observed a striking inverse relationship 
between NEDD9 expression and patient survival in the sub-set of neuroblastomas that 
lack N-myc amplification. Critically, ~65% of patients with metastatic disease have 
no N-myc amplication and variable clinical behaviours of these tumours complicate 
treatment decisions thus there is an important need for molecular markers that can 
stratify these tumours.30 Together, these analyses expand the range of tumour types in 
which high level NEDD9 expression has been correlated with reduced patient survival 
rates including melanoma6, lung adenocarcinoma31-33 and head and neck cancer.34 
 
The biophysical constraints supplied by the 3D collagen gel model allow interrogation 
of invasion plasticity as cells adopt discrete morphologies (rounded versus elongated) 
reflective of the underlying invasion machinery. Using this approach we have shown 
that NEDD9 depletion failed to induce a switch in cellular morphologies in any of the 
cell lines under investigation. Notably, siRNAb targeting NEDD9 is identical to the 
sequence previously successfully used to induce a switch to rounded invasion in 
melanoma cells (equivalent to NEDD9 OT-4 targeting sequence7). Thus it appears 
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that there may be cell-type specific differences in the effects of NEDD9 on invasion 
plasticity. Importantly, we confirmed that the SH-EP cells exhibit a robust switch to 
rounded morphology following Rac1 depletion. Thus these cells are clearly competent 
to undergo morphological transition. By contrast, the A172 glioblastoma cells 
exhibited limited morphological transition following Rac inhibition. The small 
morphological change in A172 seen following dominant negative Rac inhibition is 
likely due to the well-described non-specific inhibition of other Rho family GTPases 
following high level expression of this construct35. 
   
In contrast to our data, other high grade glioma cell lines such as the U87MG cells 
undergo morphological transition to rounded invasion following Rac inhibition.15 
Both the A172 and DBTRG cell lines are positive for nestin and DLL3 (data not 
shown), markers that are associated with the pro-neural phenotype. Potentially, the 
ability of cells to switch between invasion modes (and use different routes of invasion 
throughout the brain) may also prove to track with sub-categories of high grade 
glioma. In contrast to the A172 cells, the SH-EP cells undergo morphological 
transition following Rac1 inhibition, but this is not phenocopied by NEDD9 
inhibition. Similarly, we have previously shown that adoption of an arborized 
phenotype with neuritic membrane extensions is induced by combined NEDD9 and 
Rho kinase inhibition and cannot be blocked by Rac inhibition.23 Thus, at least in 
these two examples it appears that NEDD9 may not be regulating cellular 
morphologies via activation of Rac1 GTPase.  
 
The striking finding from our study is that in each case NEDD9 depletion 
significantly reduced the speed of 3D cell migration. Importantly, this suggests a 
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similar mechanism of NEDD9 action in these tumour types from diverse 
backgrounds. The 3D collagen matrix requires cells to either deform themselves in 
order to squeeze through pores in the matrix (rounded invasion) or alternatively 
deform the matrix via exerting force through adhesion to the matrix and secreting 
enzymes to degrade the matrix (elongated invasion).36 Significantly, NEDD9 
depletion reduced speed, without altering elongated morphologies. Similarly, let-7i 
microRNA-mediated inhibition of the Twist/NEDD9/Rac1 signalling pathway in head 
and neck cancer cells reduced the speed of elongated cell migration.34 We have 
previously shown that mouse embryo fibroblasts lacking NEDD9 expression 
exhibited reduced adhesive force to the extra-cellular matrix.16 Thus it is possible that 
the reduced migration speed exhibited following NEDD9 depletion may be due to 
decreased adhesive force to the surrounding matrix. Alternatively, given that NEDD9 
has previously been shown to modulate matrix metalloproteinase expression37, 
NEDD9 depletion may reduce matrix reorganization. Collectively, the common effect 
of NEDD9 on 3D cell speed suggests that targeting NEDD9 may be a useful 
therapeutic target in subsets of glioma and neuroblastoma tumour cells with high 
NEDD9 expression. 
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Legends 
Figure 1. NEDD9 association with survival in glioma and neuroblastoma. 
Kaplan-Meier plots comparing patient survival according to NEDD9 expression are 
shown. A. The glioma cohort was dichotomised at 2 x the median NEDD9 expression 
value. A significant difference (p = 0.01, Logrank test) was observed between high 
level (red, n = 207) and intermediate level (blue, n = 135) NEDD9 expression with 
survival. Analysis was performed on data from the REpository for Molecular BRAin 
Neoplasia DaTa (REMBRANDT) homepage (http://rembrandt.nci.nih.gov), National 
Cancer Institute, accessed 2013, October 21. B. NEDD9 expression versus tumour 
grade. Percentages of grade II/III gliomas are shown in white and grade IV 
(glioblastoma) are shaded grey. Significant differences between the proportions of 
cases with high level NEDD9 expression are indicated (Fisher’s Exact Test). C. 
Analysis of NEDD9 expression in non N-myc amplified neuroblastoma tumours30 at 
the Oncogenomics website (http://home.ccr.cancer.gov/oncology/oncogenomics/). 
These cases are all from high risk patients with metastatic disease. The cohort was 
dichotomised at 2 x the average NEDD9 expression value. A significant difference (p 
= 0.0008, Logrank test) was observed between high level (red, n = 51) and low (blue, 
n = 50) NEDD9 expression with survival. D. NEDD9 expression detected by western 
blot in 6 glioblastoma cell lines and 6 non-N-myc amplified neuroblastoma cell lines. 
NEDD9 is detected as a doublet, corresponding to 105 kDa and 115 kDa phospho-
forms. HSP70 or tubulin expression is shown as a loading control.  
 
Figure 2. NEDD9 depletion does not cause cell rounding.  
A. Western blot analysis with anti-NEDD9 antibodies showing depletion of NEDD9 
protein in A172 and DBTRG cells following NEDD9-targeted siRNA. Blots were 
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probed with anti-HSP70 antibodies to demonstrate equal loading. B. A172 and 
DBTRG cell morphology in 3D collagen gels showing examples of elongated cells 
(arrow heads) and rounded cells (arrows). C. Histogram shows the percentage of 
rounded cells under the indicated conditions. Cells were counterstained with 
propidium iodide and apoptotic cells excluded from morphological analyses. Data 
averaged from >20 fields of view with 4 x objective. ** p < 0.01, Students’ t-test. D. 
Morphology of SH-EP cells in 3D collagen gels under the indicated treatment 
conditions. Micrographs show maximum projections of confocal slices of the entire 
gel containing cells fixed and stained with fluorescently-tagged phalloidin. E. Western 
blot analysis with anti-NEDD9 antibodies showing depletion of NEDD9 protein in 
SH-EP cells following NEDD9 targeting with two independent siRNAs (a and b). 
Blots were probed with anti-HSP70 antibodies to demonstrate equal loading. F. 
Histogram shows the average numbers of rounded cells under each condition.  Data 
represent the average from 3 fields of view, >250 cells per field. * p < 0.05, Students’ 
t-test. 
 
Figure 3. DN Rac induces cell rounding. A. Histogram showing the percentages of  
cells (A172 and SH-EP, as indicated) transfected with GFP control vector or GFP 
fused to dominant negative (DN) Rac displaying a rounded phenotype. Data represent 
the average from triplicate repeats, >60 cells scored per condition, per experiment. * p  
< 0.05, ** p < 0.01, Students’ t-test. B. Bright field images of SH-EP cells in collagen 
overlayed with GFP fluorescence (10 examples shown per condition). Top panels 
show cells transfected with GFP empty vector and bottom panels with GFP.DNRac.  
Scale bar = 50 μm. 
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Figure 4. Rac1 depletion does not induce A172 rounding. A. Western blot showing 
total Rac protein levels in A172 cells following treatment with Rac1, Rac3 or 
combined Rac1/Rac3 siRNA. GAPDH levels are shown to confirm equal loading. B. 
Densitometry of total Rac protein levels following siRNA treatments as indicated. 
Data shown are the average fold change relative to controls from triplicate biological 
repeats. * p < 0.05, ** p < 0.01, *** p < 0.001, Students’ t-test. C. Micrographs 
showing maximum projections of confocal slices of collagen gels containing cells, 
fixed and stained with fluorescently-tagged phalloidin and treated as indicated. D. 
Percentage of round cells in 3D collagen gels, treated as indicated. NS = not 
significant, Students’ t-test. 
 
Figure 5. Rac1 depletion induces SH-EP cell rounding. A. Western blot showing 
total Rac protein levels in SH-EP cells following treatment with Rac1, Rac3 or 
combined Rac1/Rac3 siRNA. GAPDH levels are shown to confirm equal loading. B. 
Densitometry of total Rac protein levels following siRNA treatments as indicated. 
Data shown are the average fold change relative to controls from triplicate biological 
repeats. *** p < 0.001, NS = not significant, Students’ t-test. C. Micrographs showing 
maximum projections of confocal slices of collagen gels containing cells, fixed and 
stained with fluorescently-tagged phalloidin and treated as indicated. D. Percentage of 
round cells in 3D collagen gels, treated as indicated. * p < 0.05, NS = not significant, 
Students’ t-test. 
 
Figure 6. NEDD9 depletion reduces 3D migration speed. A. MSD calculated from 
trajectories of control (black squares) and NEDD9 siRNA-treated cells (white 
squares) in the indicated cell lines, migrating in 3D collagen gels. Data represent the 
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average of 3 (A172) and 5 (DBTRG) independent experiments (~50 cells tracked per 
experiment). B. 3D cell speed is significantly reduced following NEDD9 siRNA. ** p 
< 0.001, *** p < 0.0001, Students’ t-test. C. Frequency distribution of SH-EP cell 
speeds following NEDD9 depletion as indicated.  D. Comparison of the average SH-
EP cell migration speeds <0.4 μm/min. ** p < 0.001, *** p < 0.0001, Students’ t-test. 
E. Representative images from time-lapse series of SH-EP neuroblastoma cells in 3D 
collagen gels, showing characteristic morphologies under control conditions and 
following NEDD9 siRNA. Frames shown are from 0.5 hourly time intervals as 
indicated. Arrow heads point to the cell of interest. Scale bar, 20μm.  
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